(Q38190005)

30 August 2017

0 references

1 reference

title

The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysis (English)

1 reference

30 August 2017

1 reference

1 reference

1 reference

neoadjuvant chemotherapy

1 reference

1 reference

Fausto Petrelli

1

1 reference

30 August 2017

Andrea Coinu

2

1 reference

30 August 2017

Karen Borgonovo

3

1 reference

30 August 2017

Mary Cabiddu

4

1 reference

30 August 2017

Mara Ghilardi

5

1 reference

30 August 2017

Veronica Lonati

6

1 reference

30 August 2017

Sandro Barni

7

1 reference

30 August 2017

language of work or name

English

0 references

publication date

21 February 2014

1 reference

Breast Cancer Research and Treatment

30 August 2017

1 reference

30 August 2017

144

1 reference

30 August 2017

2

1 reference

30 August 2017

223-232

1 reference

https://scigraph.springernature.com/pub.10.1007/s10549-014-2876-z

30 August 2017

0 references

cites work

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2876-Z

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2876-Z

Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2876-Z

Molecular stratification of triple-negative breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2876-Z

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2876-Z

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2876-Z

A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2876-Z

Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2876-Z

Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2876-Z

Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2876-Z

Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2876-Z

Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2876-Z

A phase II study of sequential neoadjuvant gemcitabine plus doxorubicin followed by gemcitabine plus cisplatin in patients with operable breast cancer: prediction of response using molecular profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2876-Z

Platinum-based chemotherapy in triple-negative breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2876-Z

Multicentre phase II trial of bevacizumab combined with docetaxel-carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSG BR-0905).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2876-Z

The use of neoadjuvant platinum-based chemotherapy in locally advanced breast cancer that is triple negative: retrospective analysis of 144 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2876-Z

A Phase II trial of docetaxel and carboplatin administered every 2 weeks as preoperative therapy for stage II or III breast cancer: NCCTG study N0338.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2876-Z

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2876-Z

Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2876-Z

Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2876-Z

Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2876-Z

Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2876-Z

Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2876-Z

Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2876-Z

Response-guided neoadjuvant chemotherapy for breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2876-Z

Sequential (18)F-FDG PET/CT for early prediction of complete pathological response in breast and axilla during neoadjuvant chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2876-Z

Triple-negative breast cancer: early assessment with 18F-FDG PET/CT during neoadjuvant chemotherapy identifies patients who are unlikely to achieve a pathologic complete response and are at a high risk of early relapse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2876-Z

Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2876-Z

Bcl2 is an independent prognostic marker of triple negative breast cancer (TNBC) and predicts response to anthracycline combination (ATC) chemotherapy (CT) in adjuvant and neoadjuvant settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2876-Z

Lactate dehydrogenase B: a metabolic marker of response to neoadjuvant chemotherapy in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2876-Z

Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2876-Z

10.1007/S10549-014-2876-Z

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

30 August 2017

0 references

1 reference